Taysha Gene Therapies (TSHA) Non-Current Debt (2021 - 2026)
Taysha Gene Therapies (TSHA) posted Non-Current Debt of $49.0 million for Q1 2026, down 2.29% sequentially from $50.1 million in Q4 2025, and up 15.33% YoY from $42.5 million in Q1 2025.
Taysha Gene Therapies (TSHA) Non-Current Debt (2021 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Non-Current Debt for 6 years, with the latest figure at $49.0 million in Q1 2026.
- Quarterly Non-Current Debt rose 15.33% year-over-year to $49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.0 million (up 15.33% YoY) and the FY2025 annual result came in at $50.1 million, up 14.03% from the prior year.
- Non-Current Debt eased to $49.0 million in Q1 2026 per TSHA's latest filing, from $50.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $50.9 million in Q3 2025 and troughed at $37.4 million in Q1 2022.
- A 5-year average of $41.5 million and a median of $40.5 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 35.82% in 2022, then fell 1.35% in 2024.
- Over 5 years, Non-Current Debt stood at $38.0 million in 2022, then gained by 6.69% to $40.5 million in 2023, then gained by 8.48% to $43.9 million in 2024, then climbed by 14.03% to $50.1 million in 2025, then slipped by 2.29% to $49.0 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $49.0 million, $50.1 million, and $50.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 49.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.26 Mn |
| Mar 31, 2026 | 48.96 Mn |
| Dec 31, 2025 | 50.11 Mn |
| Sep 30, 2025 | 50.85 Mn |
| Jun 30, 2025 | 41.05 Mn |
| Mar 31, 2025 | 42.45 Mn |
| Dec 31, 2024 | 43.94 Mn |
| Sep 30, 2024 | 42.97 Mn |
| Jun 30, 2024 | 37.84 Mn |
| Mar 31, 2024 | 40.51 Mn |
| Dec 31, 2023 | 40.51 Mn |
| Sep 30, 2023 | 38.55 Mn |
| Jun 30, 2023 | 38.35 Mn |
| Mar 31, 2023 | 38.16 Mn |
| Dec 31, 2022 | 37.97 Mn |
| Sep 30, 2022 | 37.77 Mn |
| Jun 30, 2022 | 37.58 Mn |
| Mar 31, 2022 | 37.39 Mn |
| Dec 31, 2021 | 37.19 Mn |
| Sep 30, 2021 | 27.81 Mn |